

Predicting Pseudo Individual Patient-level Data with Covariates

Poster #MSR83

Verhoek A¹, Moradian H², Essink E¹, Heeg B¹

Cytel, Inc., Rotterdam, Netherlands; ²Cytel, Inc., Vancouver, Canada

Background

All indirect treatment comparisons (ITC) rely on individual patient-level data (IPD) to compare the efficacy of healthcare interventions. However, IPD are often only available for the index study while Kaplan-Meier (KM) and aggregate data are used for the comparator trials. Techniques exist to generate pseudo-IPD from KM outcome data, but this only allows estimation of the outcome and not the covariates.

Objective

This research aimed to develop a method to generate pseudo IPD by predicting the covariates on an individual patient level for use in ITCs.

Methods

The "2-opt swap & shuffling" algorithm can be considered as an imputation problem to estimate an unknown covariate X_i for subsequent analysis using the information provided by a published paper. This method relies on:

- KM data, (Y_i, S_i) , time-to-event and event status for each treatment group, and related statistics (e.g., median survival time and number of events per covariate value per treatment)
- Distribution of covariates (when x is categorical) for each treatment group
- Coefficient estimate β and the related statistics (e.g., standard errors) of a reported Cox proportional hazards model:

$$h(t) = h_0(t) \times \exp(\alpha + \beta x + \text{treatment}).$$

These inputs are used to calculate a normalized absolute error for any solution.

A better solution can be found using the algorithm as visualized in Figure 1.

Experimental testing

Several datasets were created to test the algorithm in practice:

Scenario 1. Balanced covariate distribution and regular sample size: base-case scenario with the expectation that this would be the ideal scenario for the algorithm

Scenario 2. Unbalanced covariate distribution: a skewed distribution between covariates (e.g., 30/70 split between male/female instead of 50/50) would give the algorithm both less and more space to optimize in the different subgroups.

Scenario 3. Small sample size: Fewer patients reduces the solution space, making it easier for the algorithm to find the best solution.

Scenario 4. Value of information—removing access to one or more pieces of information: Not all information could be available (e.g., the distribution of covariates might not be known). This scenario tests which information is critical.


All scenarios (except the value of information) are conducted with three sub-scenarios:

- a - Hazard ratios (HR) of both covariates are insignificant: insignificant HRs
- b - One covariate is significant, the other is insignificant: semi-significant HRs
- c - Both covariates are significant: significant HRs

This gives a total of 10 scenarios.

Methods (cont.) and Results

Figure 1. "2-opt swap & shuffling" algorithm*



*Algorithm is here used colloquially, technically the "swap & shuffle" algorithm is a heuristic since no optimal solution is guaranteed.

Table 1. Overview of the experimental testing scenarios

Scenario	Hazard ratio	Male-female	Sample size
1a	Both insignificant	50%–50%	N=287
1b*	Semi-significant	50%–50%	N=287
1c	Both significant	50%–50%	N=287
2a	Both insignificant	30%–70%	N=287
2b	Semi-significant	30%–70%	N=287
2c	Both significant	30%–70%	N=287
3a	Both insignificant	50%–50%	N=140
3b	Semi-significant	50%–50%	N=140
3c	Both significant	50%–50%	N=140
4	Semi-significant	50%–50%	N=287

Figure 2. Visualization of one of the runs in scenario 1b (base case)




Table 2a. Results of scenario 1

Run	A - Insignificant	B - Semi-significant	C - Significant
1	1.696	0.682	1.492
2	2.247	0.261	0.466
3	1.576	2.087	1.387
4	0.314	0.317	1.095
5	1.595	1.653	2.297
Average	1.486	1.000	1.347
SD	0.710	0.825	0.664

Abbreviation: SD, standard deviation

Table 2b. Results of scenario 2

Run	A - Insignificant	B - Semi-significant	C - Significant
1	1.887	0.327	Inf
2	0.790	2.150	4.196
3	0.716	0.554	0.573
4	0.816	0.809	0.932
5	2.813	3.033	0.776
Average	1.404	1.374	NA
SD	0.924	1.167	NA

Abbreviations: Inf, infinity (no solution found); NA, not applicable; SD, standard deviation

Table 2c. Results of scenario 3

Run	A - Insignificant	B - Semi-significant	C - Significant
1	0.257	3.459	0.507
2	0.593	0.329	0.709
3	0.742	4.191	3.107
4	0.354	2.268	1.561
5	0.286	0.775	1.184
Average	0.446	2.204	1.414
SD	0.211	1.665	1.032

Abbreviation: SD, standard deviation

Table 2d. Results of scenario 4*

Run	T-T-T	T-T-F	T-F-T	F-T-T	T-F-F	F-T-F	F-F-T	F-F-F
1	0.503	0.503	7.080	0.503	7.582	0.503	7.080	7.582
2	30.631	30.622	27.806	30.631	28.294	30.622	27.806	28.294
3	0.305	0.305	2.374	0.305	2.374	0.305	2.374	2.374
4	33.587	33.587	35.346	33.587	35.346	33.587	35.346	35.346
5	1.693	1.693	7.441	1.693	7.441	1.693	7.441	7.441
Average	13.344	13.342	16.010	13.344	16.208	13.342	16.010	16.208
SD	17.170	17.168	14.596	17.170	14.620	17.168	14.596	14.620

*The true-false is ordered per 1) number of events, 2) median survival, and 3) Brier score
Abbreviations: F, false; SD, standard deviation; T, true

Findings

- Scenario 1: The algorithm performed well with an almost perfect replication of the KM per subgroup.
- Scenario 2: Regenerating covariate values became more difficult, especially for the data set with only significant HRs. Here one run could not find a feasible solution
- Scenario 3: There was little effect in terms of mean error, but an increase in the standard error was observed.
- Scenario 4: The performance was mostly affected by: 1) no median and 2) combination of median and number of events.
- Sub-scenarios a/b/c: The semi-significant HR seemed to give better results, as there was more information to offset the covariates against. However, this was not necessarily the case in the other scenarios.

Conclusion

- This novel algorithm can recreate subgroup KM data for different covariates with minimal errors. The method has the potential for broader use in ITCs, such as effect-modifier testing and multivariate regression on IPD.

Presented at ISPOR US | Boston, MA | May 7–10, 2023

Contact information: www.cytel.com

Cytel